Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Gemcitabine in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
NCT04164082Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of pembrolizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by National Cancer Institute. Started Mar 2020; status: active, not recruiting.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04164082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164082.